We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $68.35 · 20 analysts
Stored first · Google News · Yahoo Finance (English)
Beximco Pharmaceuticals (BXP) H2 23/24 earnings summary - Quartr
Beximco Pharmaceuticals (BXP) H2 23/24 earnings summary Quartr
Beximco Pharmaceuticals (BXP) Q1 24/25 earnings summary - Quartr
Beximco Pharmaceuticals (BXP) Q1 24/25 earnings summary Quartr
Beximco Pharmaceuticals (BXP) H1 24/25 earnings summary - Quartr
Beximco Pharmaceuticals (BXP) H1 24/25 earnings summary Quartr
BXP Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
BXP Inc. stock underperforms Wednesday when compared to competitors MarketWatch
Ladenburg Thalmann Adjusts BXP Price Target to $80 From $70 - marketscreener.com
Ladenburg Thalmann Adjusts BXP Price Target to $80 From $70 marketscreener.com
Ladenburg Thalmann Adjusts BXP Price Target to $80 From $70
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 28. | After market close (AMC) | $0.44 | — | — | $855.73M | — | Scheduled |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $1.54 | — | — | $2.55B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $1.01 | — | — | $1.69B | Reported |
| FY2025 Q1 | 2024. 03. 31. | Time TBD | — | $0.51 | — | — | $839.44M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 28. | Truist Securities | — | Maintain | Hold → Hold | — | Truist Securities: Hold |
| 2026. 05. 18. | Barclays | — | Maintain | Overweight → Overweight | — | Barclays: Overweight |
| 2026. 05. 15. | Cantor Fitzgerald | — | Maintain | Overweight → Overweight | — | Cantor Fitzgerald: Overweight |
| 2026. 05. 15. | UBS | — | Maintain | Neutral → Neutral | — | UBS: Neutral |
| 2026. 04. 29. | Evercore ISI Group | — | Maintain | In-Line → In-Line | — | Evercore ISI Group: In-Line |
| 2026. 04. 16. | Citigroup | — | Maintain | Neutral → Neutral | — | Citigroup: Neutral |
As of FY2026 · Source: SEC/DART + price data
No holdings data to show.